A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 7 sections
Semax neuroprotection is a preclinical finding with a thin clinical layer on top. In rats and mice, Semax, the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, has been reported to raise BDNF, shift VEGF and inflammatory gene expression after experimental ischaemia, and change monoamine signalling. The human evidence is small, mostly Russian, and was not gathered in modern randomised trials. Semax is a registered medicine in Russia and not authorised in Canada, and no controlled study has characterised its long-term safety or its drug interactions.

This page sits beside three others. The ischaemia literature in detail, the comparison with Selank and the acetylated, amidated derivative each have their own article. This one asks two different questions: how wide the reported mechanism has become, and what is actually known about safety.
What does "neuroprotection" mean in the Semax papers?
In this literature the word almost always describes an experiment of one shape. An injury is induced in a rodent, usually by blocking a cerebral artery, and Semax-treated animals are compared with saline-treated ones on a molecular readout: a messenger RNA level, a protein level, a set of genes moving back toward their uninjured pattern. Sometimes a behavioural score is added.
That is a reasonable way to generate a hypothesis. It is not the same as showing that brain tissue survives in a person. A rodent stroke model produces a clean, timed injury in a young, otherwise healthy animal, while human stroke is heterogeneous in cause, timing and patient. Many compounds that looked protective in rodent ischaemia models did not carry over to human trials, which is why "neuroprotective in rats" should be read as a description of an experiment rather than a property of the molecule.
The compound's naming adds one wrinkle. Semax is usually called an ACTH(4-10) analogue, but only its first four residues come from adrenocorticotropic hormone, which is why recent papers write it as ACTH(4-7)PGP. The Pro-Gly-Pro tail was added to slow its breakdown.
How broad is the proposed mechanism?
Broad, and getting broader. Over twenty years, Semax has been reported to act on neurotrophins, blood-vessel growth genes, inflammation, monoamines, metal ions and an opioid receptor.
| Reported finding | Model | Source |
|---|---|---|
| Specific, saturable binding sites in basal forebrain membranes; BDNF protein rose in that region | Rat | Dolotov 2006, PMID 16635254 |
| Raised BDNF and trkB expression and trkB phosphorylation in the hippocampus | Rat | Dolotov 2006, PMID 16996037 |
| Changed expression of VEGF family genes after permanent arterial occlusion | Rat | Medvedeva 2013, PMID 22772900 |
| 394 genes differentially expressed after transient occlusion; inflammatory genes down, neurotransmission genes up | Rat | Filippenkov 2020, PMID 32580520 |
| Partial correction of immune and neurosignalling gene profiles 4.5 hours after transient occlusion | Rat | Filippenkov 2023, PMID 37510287 |
| Raised a serotonin metabolite in striatum; amplified amphetamine-driven dopamine release | Rodents | Eremin 2005, PMID 16362768 |
| Bound copper ions and interfered with copper-driven amyloid-beta aggregation | Cell-free and cell models | Sciacca 2022, PMID 35080861 |
| Mu-opioid receptor proposed as a target, by network pharmacology and docking, in spinal cord injury | Mouse and cell models | Liu 2025, PMID 40692165 |
Three things stand out when the findings are set side by side.
No receptor has been identified. Dolotov and colleagues showed binding that was specific, reversible and calcium-dependent, with a dissociation constant in the low nanomolar range (PMID 16635254). That is strong evidence that something in rat brain recognises Semax. It is not the identity of that something. The mu-opioid assignment in the 2025 spinal cord study came from computational docking and network analysis, and has not been confirmed by binding work in another laboratory.
Breadth cuts both ways. A molecule reported to touch neurotrophins, angiogenesis genes, inflammation, serotonin, dopamine, copper and opioid receptors either has some upstream action that nobody has yet pinned down, or some of these findings will not replicate, or both. A long list of mechanisms is often a sign that the central one is still missing.
Most of the work comes from one network. Nikolai Myasoedov, whose group at the Institute of Molecular Genetics in Moscow developed Semax, is a co-author on the binding, BDNF, VEGF, transcriptome, immune-gene and monoamine papers in the table above. The copper study from Catania and the spinal cord study from Wenzhou are independent, and they examine different questions rather than replicating the core findings.
What does the human evidence consist of?
Less than the registration might suggest, at least in the indexed literature.
The most cited clinical paper is Gusev and colleagues' 1997 study in acute hemispheric ischaemic stroke, published in Russian: 30 patients received Semax alongside standard care and were compared with 80 patients of similar stroke severity treated conventionally, using clinical rating scales, EEG mapping and evoked potentials (PMID 11517472). The abstract does not describe randomisation or blinding, and the control group was more than twice the size of the treated group. It is a comparative clinical study of its period, not a modern trial.
The other indexed human work measures brain activity rather than outcomes. Lebedeva and colleagues used resting-state functional MRI in 24 healthy volunteers, 14 given Semax and 10 placebo in the formulation studied, and reported changes in the default mode network within 20 minutes (PMID 30225715). A connectivity change on a scan in a small group is a measurement, not a clinical effect.
ClinicalTrials.gov lists no registered study of Semax. You can check the registry yourself; the search returned nothing when this page was written.
What is known about Semax safety?
Very little in a form that can be checked. The Russian clinical literature reports use in stroke and cognitive conditions over several decades, but the indexed abstracts do not include systematic adverse-event reporting, and none of that experience has been reviewed by Health Canada, the FDA or the EMA. What follows is the more useful list: the specific safety questions that have not been studied.
| Safety question | What exists | Status |
|---|---|---|
| Adverse events in controlled human trials | No modern randomised, registered trial with published adverse-event tables | Untested to current standards |
| Long-term exposure | No published long-term controlled data in people | Untested |
| Interaction with stimulants | One rodent study: Semax amplified amphetamine-driven striatal dopamine release and locomotion | A signal in animals; no human data |
| Interaction with opioids | One mouse study proposes the mu-opioid receptor as a target | Hypothesis only; no interaction study |
| Interaction with anticoagulants or antiplatelet drugs | No study found | Untested |
| Interaction with antidepressants or other serotonergic drugs | Rodent data show serotonin metabolism changes; no combination study found | Untested |
| Pregnancy, children, older adults with multiple medicines | No controlled data found | Untested |
The stimulant row is the one with real data, and it deserves to be read precisely. Eremin and colleagues found that Semax alone did not change dopamine levels in rodent striatum, but given before D-amphetamine it "dramatically enhanced" amphetamine's effect on extracellular dopamine and on locomotor activity (PMID 16362768). That is a pharmacodynamic interaction in animals. Whether anything comparable happens in people taking prescription stimulants has never been examined.
The anticoagulant row matters for a different reason. The main clinical setting in which Semax was studied is acute ischaemic stroke, where patients commonly receive antithrombotic drugs. No study we found examined the combination.
Absence of a reported interaction is not evidence of compatibility. For a compound with no identified receptor, a mechanism list this broad, and no modern interaction studies, the honest position is that interaction risk is unknown rather than low. The same reasoning applies to the derivatives: the acetylated, amidated form has even less data, because the published work was done on Semax itself.
Is Semax approved in Canada?
No. Semax is a registered medicine in Russia, where its clinical literature was produced. It is not authorised for sale as a drug by Health Canada, and it has not been approved by the FDA or the EMA for any indication. Readers can search Health Canada's Drug Product Database for any product they want to check. What Canadian rules mean for compounds like this is covered in Health Canada's rules for research peptides.
Registration in one country is a regulatory fact about that country. It does not transfer a safety review to another jurisdiction, and no regulator outside Russia has examined the Semax dossier.
Reading the Semax literature
Evidence stage. Mostly rodent and cell work on molecular endpoints; a small, older, largely Russian clinical record; one small imaging study in healthy volunteers.
Strongest result. Specific binding in rat brain and a rise in BDNF, from one group, not yet tied to an identified receptor.
Weakest link. Safety and interactions, where the literature is close to silent.
For a framework for judging studies of this kind, see how to read a peptide study. Nothing here is medical, dosing, or therapeutic guidance.
Supplied here for laboratory use: Semax. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
Frequently asked questions
Is Semax proven to be neuroprotective in people? No. The neuroprotection findings come from rodent models of induced ischaemia, measured mostly as gene and protein expression. The human evidence is a small number of older Russian clinical studies without modern randomisation, plus one small imaging study. No regulator outside Russia has reviewed it, and no registered trial appears on ClinicalTrials.gov.
How does Semax affect BDNF? In rats, Dolotov and colleagues reported that Semax raised BDNF protein in the basal forebrain and raised BDNF and trkB expression in the hippocampus. Those are measurements in rodent brain tissue. Whether the same happens in people, and whether a BDNF change would translate into any functional effect, has not been established.
What receptor does Semax act on? Nobody knows for certain. Specific, high-affinity binding sites have been shown in rat brain membranes, but the receptor protein has not been identified. A 2025 mouse study proposed the mu-opioid receptor, based on computational docking and network analysis, which has not been confirmed independently.
Does Semax interact with stimulants or other medicines? No interaction study has been done in people. In rodents, Semax amplified amphetamine-driven dopamine release and locomotor activity, which is a signal worth taking seriously. Interactions with opioids, anticoagulants and serotonergic drugs have not been studied at all, so the risk is unknown rather than low.
Why is Semax legal in Russia but not approved in Canada? Russia registered it on the strength of domestic clinical research. Health Canada, the FDA and the EMA have not reviewed or authorised it, so it has no status as a medicine here. Material sold in Canada as a research chemical is for laboratory use only, not for human use.
Selected Research References
- Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry. 2006;97 Suppl 1:82-86. pubmed.ncbi.nlm.nih.gov/16635254
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. pubmed.ncbi.nlm.nih.gov/16996037
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. Effect of Semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischemia of the rat brain. Journal of Molecular Neuroscience. 2013;49(2):328-333. pubmed.ncbi.nlm.nih.gov/22772900
- Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes. 2020;11(6):681. pubmed.ncbi.nlm.nih.gov/32580520
- Filippenkov IB, Remizova JA, Stavchansky VV, et al. Synthetic adrenocorticotropic peptides modulate the expression pattern of immune genes in rat brain following the early post-stroke period. Genes. 2023;14(7):1382. pubmed.ncbi.nlm.nih.gov/37510287
- Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research. 2005;30(12):1493-1500. pubmed.ncbi.nlm.nih.gov/16362768
- Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. Semax, a synthetic regulatory peptide, affects copper-induced Abeta aggregation and amyloid formation in artificial membrane models. ACS Chemical Neuroscience. 2022;13(4):486-496. pubmed.ncbi.nlm.nih.gov/35080861
- Liu R, Chen Y, Huang H, et al. Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology. 2025;182(22):5489-5516. pubmed.ncbi.nlm.nih.gov/40692165
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 1997;97(6):26-34. pubmed.ncbi.nlm.nih.gov/11517472
- Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the default mode network of the brain. Bulletin of Experimental Biology and Medicine. 2018;165(5):653-656. pubmed.ncbi.nlm.nih.gov/30225715
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
